Quercetin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Quercetin dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Quercetin.
Dosing Protocols
Beginner protocol — general antioxidant and allergy support:
Step 1: Assess the primary reason for supplementation. Common starting indications are seasonal allergic rhinitis, chronic urticaria, mild hypertension, general antioxidant support, or inclusion in a broader polyphenol stack. Align the dose and form with the indication.
Step 2: Choose a bioavailability-enhanced form. For most users, EMIQ (enzymatically modified isoquercitrin, alpha-glycosyl isoquercitrin) or quercetin phytosome (Quercefit) provides 5-20-fold better absorption than standard quercetin aglycone at equivalent label dose. The small price premium is clinically meaningful because many of quercetin's effects require plasma concentrations that unenhanced aglycone supplements struggle to achieve.
Step 3: Begin at 250-500 mg once daily with a meal containing some fat. Assess tolerability (gastrointestinal, headache) over 5-7 days. Most users tolerate this dose without issue.
Step 4: If the initial dose is well-tolerated and targeting allergy or blood pressure endpoints, increase to 500 mg twice daily (breakfast and evening meal) at week 2. Common allergy dosing is 500 mg two or three times daily during symptomatic periods.
Step 5: Continue for at least 4-8 weeks before evaluating effect. Blood pressure effects emerge over 4-8 weeks; allergy effects may be noticeable more quickly (days to 2 weeks). Senolytic effects and cardiovascular benefits require longer time horizons (months).
Step 6: Combine with supporting ingredients — vitamin C 500 mg daily at the same meal (synergistic for allergy and antioxidant function), bromelain 200-500 mg twice daily if targeting allergy (often co-formulated in allergy-focused quercetin products), and standard multivitamin/omega-3 foundation.
Step 7: Dietary support — incorporate quercetin-rich foods regularly: red onions (especially raw in salads), apples with peel, berries (blueberries, blackcurrants, cranberries), leafy greens, capers, and green tea. This maintains tissue exposure to diverse polyphenols and supports gut microbiota that produce quercetin's bioactive metabolites.
Intermediate protocol — specific clinical indications:
Step 1: Allergic rhinitis and perennial allergies — quercetin 500 mg two to three times daily (bioavailability-enhanced form) combined with bromelain 500 mg twice daily, vitamin C 500-1000 mg, and NAC 600-1200 mg. Begin 4-6 weeks before expected allergy season for maximum prophylactic benefit. Continue through the allergic period. May supplement or partially replace antihistamine medications depending on severity and clinical response; partner with allergy specialist if severe.
Step 2: Chronic urticaria and mast cell activation syndrome — quercetin 500-1000 mg twice daily combined with vitamin C, stinging nettle 500 mg twice daily, and H1/H2 antihistamine coverage as needed. Consider broader mast cell activation workup if symptoms are severe or multisystem.
Step 3: Stage 1 hypertension (systolic 130-139 or diastolic 80-89 mmHg) — quercetin 730-1000 mg daily (the Edwards 2007 protocol used 730 mg) for 8-12 weeks to assess response. Most clinically useful as an adjunct to lifestyle measures or alongside first-line antihypertensive therapy; effect size is modest (3-7 mmHg) but meaningful in combination. Monitor blood pressure weekly for 4 weeks then every 2-4 weeks.
Step 4: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) — quercetin 500 mg twice daily for at least 4 weeks. Shoskes 1999showed symptom improvement in 67% of patients with CP/CPPS. Often combined with bromelain, saw palmetto, stinging nettle root, and urological management.
Step 5: Interstitial cystitis/painful bladder syndrome — quercetin 500 mg twice daily (Katske 2001 protocol) as part of a multi-modal approach with dietary modification and urological care. Pairs well with bromelain and papain.
Step 6: Exercise performance support for endurance athletes — quercetin 1000 mg daily (splitted 500 mg twice daily) for 1-2 weeks before competitive events and during training periods. Pairs well with omega-3, vitamin C, and green tea extract. Effect size is modest (3% endurance improvement per Davis 2010) but clinically meaningful at competitive levels.
Step 7: General cardiovascular and anti-inflammatory stacking — quercetin 500-1000 mg daily as part of a polyphenol stack with resveratrol, curcumin, and EGCG. Long-term maintenance. Complement with dietary intake of quercetin-rich foods.
Advanced protocol — specialist senolytic and research applications:
Step 1: Senolytic D+Q combination protocol — dasatinib 100 mg + quercetin 1000 mg once daily for 3 CONSECUTIVE DAYS administered monthly or quarterly. This is a SPECIALIST MEDICAL SUPERVISION protocol requiring a prescription for dasatinib (a tyrosine kinase inhibitor with significant side effects: myelosuppression, edema, QT prolongation, bleeding, pleural effusion, drug interactions). DO NOT SELF-ADMINISTER D+Q. Clinical trial protocols use intermittent dosing specifically because continuous senolytic exposure is unnecessary and may have adverse effects on tissue renewal. Active trials are recruiting in IPF (LaPP), Alzheimer's disease, osteoarthritis, and frailty — potentially available as research participation.
Step 2: Fisetin-based senolytic alternative — fisetin at 20 mg/kg for 2 consecutive days monthly is an active research senolytic protocol available without prescription. Can be used as a self-administered alternative to D+Q under appropriate clinical context with lower but still non-trivial complexity. Quercetin is sometimes added at 500-1000 mg during fisetin dosing days.
Step 3: Drug interaction screening before quercetin supplementation — review concomitant medications for interactions. Critical interactions: cyclosporine (avoid), fluoroquinolones (time-separate), warfarin (monitor INR), digoxin (monitor level), tyrosine kinase inhibitor chemotherapy (specialist required). Moderate interactions: CYP3A4-metabolized drugs (statins, some antihypertensives), P-gp substrates, chemotherapy agents. Adjust quercetin dose or timing accordingly.
Step 4: Genetic variant considerations — COMT (catechol-O-methyltransferase) polymorphisms may affect quercetin methylation to isorhamnetin. Low-activity COMT variants may have relatively higher circulating active quercetin. CYP3A4/5 polymorphisms affect interaction risk with comedications. Not routinely clinical but relevant in research contexts.
Step 5: Quercetin IV formulations (experimental) — some research protocols have tested intravenous quercetin at 60-1700 mg/m². One case report of renal injury (Choi 2000) has raised caution. IV quercetin is not a routine clinical practice; remain in oral supplementation for almost all purposes.
Step 6: Bioavailability optimization in non-responders — if clinical response is inadequate at standard doses with standard aglycone, switch to phytosome or EMIQ formulation which may achieve clinical response at the same nominal dose. For research-grade bioavailability, Quercefit (Indena) or proprietary phytosome formulations are well-characterized.
Step 7: Combination research — quercetin is often tested in combination with other polyphenols (EGCG, resveratrol, curcumin) and with zinc for antiviral mechanisms. Combination protocols require more careful dose titration and drug interaction assessment than single-compound use.
Step 8: Long-term monitoring — for patients on continuous quercetin 500-1000 mg daily for >6 months, periodic review of complete blood count, comprehensive metabolic panel, and any relevant target disease markers is reasonable. No specific quercetin-related laboratory changes are expected but general supplementation monitoring is prudent.
Step 9: Discontinuation — no tapering is required. Effects are dose-dependent and emerge/resolve on a pharmacokinetic timescale (hours to days). No withdrawal syndrome.
Step 10: Integration with specific disease trials — patients with conditions under active quercetin research (IPF, Alzheimer's disease, diabetic kidney disease, long COVID, post-COVID fatigue syndromes) should consider trial participation over open-label supplementation when feasible to contribute to evidence development and receive structured monitoring.
Commonly Stacked With
Quercetin stacks with a broad array of polyphenols, minerals, vitamins, and other bioactive compounds across the allergy/histamine, cardiovascular, senolytic, exercise, and general antioxidant arcs.
For allergy and mast cell stabilization, quercetin combines with bromelain 200-500 mg daily (pineapple-derived protease that may enhance quercetin absorption and has its own anti-inflammatory effects — often co-formulated in allergy-focused products), stinging-nettle 300-500 mg daily (traditional allergy botanical), vitamin-c 500-1000 mg daily (cofactor in histamine degradation, regenerates oxidized quercetin, amplifies antihistamine effect), N-acetyl-cysteine 600-1200 mg daily (glutathione precursor, reduces mucosal oxidative stress), vitamin-d3 2000-5000 IU daily (immunomodulation particularly relevant to allergic sensitization), and omega-3 1-2 g daily (anti-inflammatory resolvin production). This stack addresses the multiple pathways involved in allergic rhinitis, urticaria, and environmental allergy beyond simple histamine blockade.
For cardiovascular prevention and blood pressure management, quercetin pairs with CoQ10 100-200 mg daily (mitochondrial support, synergistic with quercetin for endothelial function), resveratrol 150-500 mg daily (stilbene polyphenol synergy, SIRT1 activation), pterostilbene 50-150 mg daily (more bioavailable resveratrol analog), magnesium 200-400 mg daily (vascular smooth muscle relaxation), omega-3 1-2 g daily, vitamin-k2 MK-7 100-200 mcg (arterial calcium management), and taurine 1-3 g daily (vascular tone). The polyphenol-mineral-lipid stack addresses multiple cardiovascular risk factors with complementary mechanisms.
For senolytic applications, quercetin is classically paired with prescription dasatinib (Sprycel) in the D+Q protocol popularized by Kirkland et al. Typical dosing is dasatinib 100 mg + quercetin 1000 mg daily for 3 consecutive days administered monthly or quarterly. This is a SPECIALIST MEDICAL SUPERVISION protocol — dasatinib is a prescription tyrosine kinase inhibitor with substantial side effects and drug interactions, and should never be self-administered. Clinical trials of D+Q are ongoing in multiple indications. Alternative senolytic stacks without prescription requirements include fisetin 500-1500 mg daily (another flavonoid senolytic with better bioavailability than quercetin aglycone) and curcumin with enhanced absorption (Meriva, Longvida) for complementary anti-senescence effects.
For exercise performance and recovery, quercetin combines with beta-alanine 3-5 g daily (carnosine support for muscular buffering), creatine 3-5 g daily (phosphocreatine energy system), L-citrulline 3-6 g daily (nitric oxide for endurance), CoQ10 100-200 mg, omega-3 1-2 g, vitamin-c, and vitamin-e 200-400 IU. For endurance athletes specifically, Nieman's research group has tested quercetin 1000 mg + EGCG 400 mg + fish oil as a performance stack with modest benefit.
For general anti-inflammatory and antioxidant stacks, quercetin combines with curcumin phytosome 500-1000 mg (bioavailability-enhanced turmeric), resveratrol 150-500 mg, pterostilbene 50-150 mg, green-tea-extract or EGCG 300-500 mg, pycnogenol 100-200 mg (French maritime pine bark procyanidins), grape-seed-extract 150-300 mg, astaxanthin 4-8 mg, milk-thistle 150-300 mg (silymarin for liver support), alpha-lipoic-acid 300-600 mg, and glutathione 250-500 mg. This polyphenol-dominant stack provides broad antioxidant and anti-inflammatory coverage across multiple tissue compartments.
For COVID/respiratory infection prophylaxis contexts (considering preliminary evidence), quercetin combines with zinc 15-30 mg daily (zinc ionophore mechanism, quercetin facilitates intracellular zinc transport), vitamin-c 500-1000 mg, vitamin-d3 2000-5000 IU, NAC 600-1200 mg, and elderberry 500-1000 mg (Sambucol or equivalent). Note: the evidence for quercetin-based antiviral stacks is preliminary and the clinical significance for COVID-19 or other respiratory infections is not definitively established.
For interstitial cystitis and chronic pelvic pain, quercetin 500 mg twice daily (Katske 2001 protocol) combines with bromelain, papain, curcumin, and appropriate urological management.
For prostatitis, quercetin 500 mg twice daily (Shoskes 1999 protocol) combines with saw-palmetto, stinging-nettle-root, and appropriate urological workup.
Dietary enhancement of quercetin bioavailability:
-
Co-consumption with dietary fats — moderate benefit; take with meals rather than on an empty stomach.
-
Co-consumption with quercetin-metabolism cofactors — vitamin C regenerates oxidized quercetin extending its antioxidant function; this is synergistic rather than purely bioavailability-enhancing but is practical to pair in the same meal.
-
Choice of bioavailability-enhanced form — EMIQ (alpha-glycosyl isoquercitrin) and quercetin phytosome (Quercefit, Quercetin Phytosome) provide 5-20-fold higher plasma concentrations than aglycone and are worth the price premium for cost-effectiveness.
-
Avoidance of high-tannin foods at the same meal — tea, wine, and high-tannin foods can form insoluble complexes with quercetin reducing absorption; separate by 1-2 hours.
-
Gut microbiota health — quercetin is extensively metabolized by gut bacteria and the bioactive phenolic acids produced contribute to systemic effects. Fiber-rich diet supporting gut microbiota diversity enhances quercetin metabolism.
Timing: Plasma half-life of quercetin-3-glucuronide is 12-17 hours. Once or twice daily dosing is pharmacokinetically adequate. For acute allergy management, splitting dose to 500 mg twice daily may provide more consistent symptom coverage than single daily dose.
Stacks to avoid or time-separate:
- Cyclosporine — avoid co-administration.
- Fluoroquinolone antibiotics — separate by 2-4 hours during active antibiotic courses.
- Iron supplementation — separate by 2-4 hours if both are being actively supplemented.
- Warfarin — coordinate with anticoagulation management.
- Tyrosine kinase inhibitor chemotherapy — only use D+Q combination under oncologic supervision.
Canonical recommendation: 500-1000 mg daily of a bioavailability-enhanced form (EMIQ, phytosome, or Quercefit) with meals, stacked with vitamin C 500 mg and bromelain 200-500 mg for allergy; paired with cardiovascular or polyphenol stacks as clinical context dictates; reserved in senolytic applications for specialist medical supervision of the D+Q combination.
Side Effects & Safety
Contraindications
Contraindications for quercetin supplementation are generally relative rather than absolute, with the most clinically important being specific drug interactions. Absolute contraindications: None in typical adults at standard supplementation doses. Quercetin has an exceptionally favorable safety profile across multiple large studies. Relative contraindications and caution situations: Cyclosporine therapy — quercetin substantially increases cyclosporine exposure through CYP3A4 and P-glycoprotein inhibition. Avoid quercetin supplementation in solid organ transplant recipients or other cyclosporine users without specialist supervision. Warfarin anticoagulation — quercetin has modest antiplatelet activity and weak CYP2C9 inhibition. Monitor INR at 1-2 weeks after starting or stopping quercetin. Often does not require warfarin dose adjustment but occasional clinically meaningful interactions occur. Digoxin — quercetin inhibits P-glycoprotein, potentially increasing digoxin absorption. Monitor digoxin levels when adding quercetin. Tyrosine kinase inhibitor chemotherapy (dasatinib, imatinib, erlotinib, gefitinib, sunitinib) — quercetin has its own tyrosine kinase inhibition which may improve or alter the therapeutic or toxic effects. The D+Q senolytic combination is an intentional synergy requiring specialist supervision. Outside of intentional senolytic use, oncology patients should discuss supplementation with their oncologist. Fluoroquinolone antibiotics — quercetin binds to DNA gyrase at the same binding site as fluoroquinolones, potentially antagonizing antibacterial activity. Separate doses by 2-4 hours or suspend quercetin during active fluoroquinolone therapy. Some chemotherapy agents (paclitaxel, doxorubicin, vinca alkaloids) — CYP3A4 and P-gp substrates may have altered exposure. Discuss with oncologist. Some statins (simvastatin, atorvastatin, lovastatin) — CYP3A4 and OATP1B1 effects may increase statin exposure. Clinically meaningful interaction is uncommon at typical doses but possible at high quercetin doses. Antihypertensive medications — quercetin's modest blood pressure lowering effect may be additive. Monitor BP and adjust as needed. Antiplatelet medications (aspirin, clopidogrel, prasugrel) — additive bleeding risk. Usually not clinically significant at standard doses but monitor if both are prescribed. Iron supplementation — chelation reduces iron absorption. Separate by 2-4 hours if both are being actively supplemented. Pregnancy — dietary intake through food is unambiguously safe. Supplementation at typical doses (500-1000 mg daily) during pregnancy has limited safety data. Conservative practice is to rely on dietary intake and avoid high-dose supplementation during pregnancy without specific medical indication. Lactation — limited data at supplementation doses. Dietary intake is safe. Standard supplementation doses considered low-risk. Pediatric use — not routinely indicated. Dietary intake through food is beneficial. Specific pediatric indications (chronic urticaria, allergic rhinitis) may warrant supplementation under allergist or pediatric specialist supervision. Renal impairment — one case report of acute renal injury with IV quercetin at 1700 mg/m² has raised theoretical caution at very high doses. Oral quercetin at typical supplementation doses has not shown renal toxicity. Patients with pre-existing severe renal impairment should use moderate doses with clinical monitoring. Hepatic impairment — no specific hepatotoxicity identified. Conjugation is reduced in severe liver disease potentially altering pharmacokinetics. Monitor clinical response. Thyroid disease — quercetin inhibits thyroid peroxidase at high in vitro concentrations. No clinical thyroid dysfunction from supplementation has been reported. Patients with autoimmune thyroid disease can use typical doses but should discuss with endocrinologist if symptomatic changes occur. Hormone-sensitive cancers — quercetin has weak phytoestrogenic activity. Theoretical caution exists in active estrogen-sensitive cancers. Dietary intake is acceptable; specialist consultation warranted before high-dose supplementation. Surgical planning — the antiplatelet effect warrants discontinuation 2 weeks before scheduled surgery to minimize bleeding risk. Severe or uncontrolled hypertension — quercetin's blood pressure lowering effect is modest but can be additive with antihypertensive therapy. Monitor carefully; do not rely on quercetin for uncontrolled hypertension requiring prescription management. Known allergy to quercetin source material — patients with oral allergy syndrome to apples, onions, or other quercetin-rich foods may have reactions to natural-source-derived quercetin supplements. Synthetic quercetin or different-source extracts may be alternatives. Gout — theoretical benefit through xanthine oxidase inhibition; no established dosing protocol for gout but some patients use as adjunctive therapy. IV quercetin — avoid outside of research contexts. Oral is the established route. Extreme doses (2000+ mg daily) for prolonged periods — long-term safety less characterized than standard dosing ranges. Use moderate doses (500-1000 mg daily) for maintenance; reserve higher doses for short-term specific indications. Children with allergic conditions — pediatric use of quercetin for allergic rhinitis has limited data; pediatric-specific dosing and safety assessment should be guided by allergy or pediatric specialist. Overall, quercetin supplementation at doses of 500-1000 mg daily in most adults has a favorable risk-benefit profile. The main practical considerations are drug interactions (cyclosporine, warfarin, fluoroquinolones, tyrosine kinase inhibitors), surgical bleeding risk, iron absorption competition, and the need for bioavailability-enhanced forms to reach therapeutic plasma concentrations. The D+Q senolytic combination is a specialist supervision protocol and should not be self-administered.
Additional Notes
Standard adult dose for general antioxidant support: 500 mg once daily of a bioavailability-enhanced quercetin (EMIQ, phytosome, or Quercefit) with a meal.
Allergic rhinitis/urticaria dose: 500 mg two to three times daily during symptomatic periods. Begin 4-6 weeks before allergy season for prophylactic benefit. Often combined with bromelain 200-500 mg per dose.
Blood pressure reduction dose: 730-1000 mg daily (Edwards 2007 protocol). Duration 8-12 weeks for assessment.
Chronic prostatitis/CP/CPPS dose: 500 mg twice daily for 4 weeks minimum (Shoskes 1999 protocol).
Interstitial cystitis dose: 500 mg twice daily (Katske 2001 protocol).
Exercise performance dose: 1000 mg daily (split 500 mg twice daily) for 1-2 weeks preceding competition or during training periods.
Senolytic D+Q dose (specialist only): dasatinib 100 mg + quercetin 1000 mg daily for 3 consecutive days, monthly or quarterly.
Fisetin-based alternative senolytic: fisetin 20 mg/kg for 2 days monthly; quercetin 500-1000 mg added during fisetin days.
Dietary equivalents:
- 100 g fresh capers: 180-230 mg
- 100 g raw red onion outer rings: 30-50 mg
- 100 g raw yellow onion: 10-20 mg
- 1 medium apple with peel: 4-10 mg
- 100 g blueberries: 2-8 mg
- 100 g black currants: 12-16 mg
- 100 g raw kale: 2-8 mg
- 1 cup green tea brewed: 2-5 mg
- Typical Western daily intake: 15-40 mg
Timing: With meals for optimal absorption. Plasma half-life 12-17 hours supports once or twice daily dosing. For acute symptomatic relief (e.g., allergic rhinitis), twice-daily dosing provides more consistent coverage.
Duration: Long-term indefinite use is appropriate for chronic indications (cardiovascular, perennial allergy, polyphenol stacking). Short-term pulses for specific indications (exercise pre-competition, senolytic cycles).
Cooking effects: Quercetin is relatively heat-stable. Cooked onions retain most quercetin. Boiling in large water volumes can leach quercetin into cooking water (soup base) — save the water for stock.
Pediatric use: Not routinely indicated. Dietary intake through food is safe and beneficial.
Pregnancy: Dietary intake is safe. Supplementation data limited; high-dose use during pregnancy should be discussed with obstetrician.
Lactation: Safe at dietary intake levels. Supplementation data limited.
Geriatric use: No dose adjustment. Older adults may benefit from bioavailability-enhanced forms due to reduced baseline absorption efficiency.
Renal impairment: No formal dose adjustment. Avoid high-dose IV quercetin. Oral quercetin at typical doses has no specific renal dosing.
Hepatic impairment: Hepatic conjugation is reduced in severe liver disease, potentially altering quercetin metabolism. No established dose adjustment. Monitor clinical response.
Drug interactions (dose-relevant):
- Cyclosporine: avoid or require specialist dose adjustment.
- Warfarin: monitor INR; dose increase may require anticoagulation adjustment.
- Digoxin: monitor level; may require digoxin dose reduction.
- Fluoroquinolones: time-separate by 2-4 hours.
- Tyrosine kinase inhibitor chemotherapy: only combine under oncologic supervision.
- CYP3A4-metabolized drugs at high doses: consider interaction potential.
Brand notes:
- EMIQ (enzymatically modified isoquercitrin): high bioavailability, good evidence base.
- Quercefit/Quercetin Phytosome (Indena): sunflower lecithin phytosome, 20-fold bioavailability enhancement.
- QuerceMax, QU995: quality aglycone standardized products.
- Thorne Research, Pure Encapsulations, Designs for Health: reputable supplement manufacturers with quality control.
- Avoid unknown-origin products or deeply discounted unverified brands.
Common mistakes: (1) Using unenhanced aglycone and not reaching therapeutic plasma concentrations. (2) Taking on empty stomach — reduces absorption. (3) Taking with iron supplements — chelation reduces iron absorption. (4) Continuing during warfarin anticoagulation without INR monitoring. (5) Combining with cyclosporine — avoid. (6) Short duration expectations for blood pressure or senolytic endpoints — these require 8-12 weeks or months. (7) Self-administering D+Q without prescription and specialist supervision.
Frequently Asked Questions
What is the recommended Quercetin dosage?
Dosage for Quercetin varies by protocol. Consult a qualified healthcare provider.
How often should I take Quercetin?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Quercetin need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Quercetin side effects?
Quercetin has a favorable safety profile at typical supplementation doses with few serious adverse events reported in clinical trials up to 1500 mg daily for 12 weeks and extended use at 500-1000 mg daily. Dietary intake through food is universally safe. Gastrointestinal tolerance is generally good. Reported effects include mild nausea, gastric discomfort, loose stools, and bloating at doses above 1000 mg daily, typically mitigated by taking with food or dividing into multiple daily doses. Rare reports of more severe gastrointestinal symptoms occur with quercetin aglycone at very high doses (2000+ mg daily). Headache: mild transient headache has been reported at initiation of high-dose supplementation, usually resolving within 2-3 days. Paresthesia and peripheral tingling: rare reports at doses above 1000 mg daily; mechanism unclear, reversible on dose reduction. Renal concerns: a single case report (Choi 2000) of acute renal injury with intravenous quercetin at 1700 mg/m² in a cancer patient study. Oral quercetin at typical supplementation doses has not been associated with renal dysfunction. High-dose oral quercetin should be used cautiously in patients with pre-existing renal impairment, though no clear dose-limiting renal signal exists. Drug interactions — clinically significant and warranting attention: - Cyclosporine: quercetin increases cyclosporine levels through CYP3A4 and P-glycoprotein inhibition. Clinically significant interaction; patients on cyclosporine should avoid quercetin supplementation or require dose adjustment under specialist supervision. - Warfarin and anticoagulants: quercetin has weak antiplatelet and anticoagulant activity and modest CYP2C9 inhibition. Warfarin patients should monitor INR carefully if adding quercetin; the interaction is usually mild but can accumulate. - Digoxin: quercetin inhibits P-glycoprotein which may increase digoxin absorption. Monitor digoxin levels if adding quercetin. - Fluoroquinolones: quercetin may antagonize fluoroquinolone antibacterial activity by binding DNA gyrase at the same site. Separate doses by 2-4 hours or avoid during active fluoroquinolone therapy. - Some statins: quercetin modestly inhibits CYP3A4 and OATP1B1, which may increase exposure to simvastatin, atorvastatin, and lovastatin. Clinically meaningful interaction is uncommon at typical doses but possible at high doses. - Chemotherapy agents: quercetin's P-glycoprotein and CYP3A4 effects may interact with chemotherapy agents that are P-gp or CYP3A4 substrates (paclitaxel, doxorubicin, etoposide, vinca alkaloids, tamoxifen). Oncology patients should discuss supplementation with their oncologist before adding quercetin. - Tyrosine kinase inhibitors (dasatinib, imatinib, gefitinib, erlotinib): quercetin has its own tyrosine kinase inhibition; the senolytic D+Q combination is an intentional synergy but in other oncologic contexts the combination may have unintended effects. Specialist oversight required. - Antihypertensive medications: quercetin's modest blood-pressure-lowering effect may be additive with prescribed antihypertensives. Monitor blood pressure and adjust as needed. Pregnancy: human safety data at supplementation doses are limited. Dietary intake through food is unambiguously safe and encouraged. High-dose supplementation during pregnancy is generally avoided in the absence of specific medical indication. Lactation: limited data. Dietary intake is safe. Supplementation at typical doses is considered low-risk but not well-studied. Pediatric use: not routinely indicated for healthy children. Dietary intake is beneficial. Specific medical indications (pediatric allergic rhinitis, chronic urticaria) may warrant supplementation under pediatric or allergy specialist guidance. Liver function: generally not adversely affected. Case reports of hepatitis associated with quercetin-containing supplements have typically involved complex formulations with other ingredients and unclear causal attribution. Thyroid function: quercetin can inhibit thyroid peroxidase and sodium-iodide symporter at high concentrations in vitro. Clinical thyroid dysfunction from quercetin supplementation has not been reported. Patients with Hashimoto thyroiditis or pre-existing thyroid disease should discuss supplementation with their endocrinologist. Iron absorption: quercetin chelates iron and can modestly reduce dietary non-heme iron absorption when taken at the same meal. Patients with iron deficiency anemia should separate iron supplementation from quercetin dosing by 2-4 hours. Hormone-sensitive conditions: quercetin has weak phytoestrogenic activity. Theoretical concerns in estrogen-sensitive cancers have been raised but epidemiologic data do not support harm; practical guidance is to maintain dietary intake through food and use supplementation only with specialist guidance in active estrogen-sensitive cancer contexts. Surgery: the antiplatelet effect may warrant discontinuation 2 weeks before scheduled surgery to minimize bleeding risk. Discuss with surgical team. Extremely high-dose research protocols (2000+ mg daily): most safety data are from short-term trials; long-term safety at doses above 1500 mg daily is less well-characterized. Conservative practice is to use moderate doses (500-1000 mg daily) for maintenance and reserve higher doses for specific short-term indications. Allergy: quercetin itself is not a common allergen. Supplement excipients (gelatin capsules, vegetable fillers) may cause reactions in sensitive individuals. Natural source materials (onions, apples) can cause allergies in those with pre-existing oral allergy syndromes. Overall, quercetin supplementation at doses of 500-1500 mg daily in most adults for typical indications is well-tolerated. The main practical considerations are: (1) drug interactions with cyclosporine, warfarin, some statins, and certain chemotherapy agents; (2) surgical bleeding risk; (3) iron absorption competition with concurrent iron supplementation; and (4) limited pregnancy data suggesting caution with high-dose supplementation. The risk-benefit profile is favorable for most adult users with appropriate clinical context.
Where can I buy Quercetin?
Visit our vendor directory to find trusted sources for Quercetin.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
